Last updated: March 13, 2026
What is the Drug with NDC 43386-0371?
NDC 43386-0371 corresponds to Sodium Oxybate (brand name: Xyrem). It is indicated for the treatment of narcolepsy with cataplexy and other sleep disorders. Approved by the FDA in 2002, sodium oxybate is classified as a central nervous system depressant.
Market Overview
Market Size and Revenue
The sodium oxybate market primarily comprises patients with narcolepsy and other sleep-related disorders. In the United States, approximately 135,000 individuals are diagnosed with narcolepsy (Gabbott et al., 2018). Commercial sales depend on prescription volume, with most prescriptions dispensed through specialty pharmacies.
Total U.S. sales are estimated at approximately $1.2 billion annually (IQVIA, 2022), owing to high pricing and market share dominance by the original manufacturer, Jazz Pharmaceuticals.
Competition and Market Share
- Jazz Pharmaceuticals: The sole marketed product, Xyrem.
- Off-label and alternative therapies: Modafinil, armodafinil, and stimulants such as amphetamines.
- Emerging treatments: GABA_B receptor modulators and other sleep disorder drugs are in clinical development but have not yet impacted the sodium oxybate market significantly.
Regulatory Environment and Future Approvals
- The US FDA approved a low-sodium formulation, Xywav, in 2020, targeting a lower sodium dose while maintaining efficacy.
- Xywav has gained market traction among patients with sodium restrictions, potentially reducing Xyrem’s market share.
Patent and Exclusivity Timeline
- Xyrem's original patent expired in 2017.
- Extended exclusivity periods have delayed generic entry until at least 2024.
- Patent litigations and settlement agreements have influenced generic availability.
Price Projections
Current Pricing
- Average wholesale price (AWP): Approximately $66 per 10 mL vial.
- Typical monthly prescription: 30-40 vials, resulting in $2,000-$2,640 monthly per patient.
- Annual revenue per patient: $24,000-$32,000.
Future Price Trends
- The arrival of generics is projected around 2024, leading to a potential price decrease of 30-50%.
- Xywav, launched at a comparable price point, may keep overall treatment costs stable or slightly reduce prices for sodium oxybate formulations.
- The industry trend favors price erosion as biosimilars and generics enter the market.
Market Penetration and Volume Forecasts
| Year |
Prescriptions Estimated |
Revenue Projection |
Notes |
| 2023 |
45,000-50,000 |
~$1.1-$1.4 billion |
Xyrem dominance, limited generics |
| 2024 |
35,000-45,000 |
~$700 million-$1.2 billion |
Entry of generics influences prices |
| 2025+ |
Stabilization at lower prices |
$500-$700 million |
Market adjustments, patent expiries |
Drivers of Price Changes
- Competition from authorized generics and biosimilars.
- Pricing pressure from payers and insurance companies.
- Market adoption of Xywav, which may cap price increases.
Key Considerations for Stakeholders
- Patent expiration timing significantly affects generic competition and pricing.
- The emergence of low-sodium formulations impacts the market share of the original drug.
- The small patient population limits volume but sustains high per-unit pricing.
Key Takeaways
- NDC 43386-0371 (Xyrem) dominates the narcolepsy treatment market with annual revenues around $1.2 billion.
- The market is expected to face price declines starting in 2024 due to generic competition.
- The introduction of Xywav offers alternative pricing dynamics, with potential to influence overall sodium oxybate market prices.
- Population size will limit volume increases, but high treatment costs sustain revenue.
- Patent expiry and regulatory decisions are primary factors driving future price trends.
FAQs
1. When will generic versions of sodium oxybate become available?
Patents for Xyrem expired in 2017; however, patent litigations and settlements have pushed generic entry to approximately 2024.
2. What factors influence sodium oxybate pricing?
Pricing is influenced by patent status, competition from generics or biosimilars, regulatory approvals of formulations like Xywav, and payer policies.
3. How does the introduction of Xywav affect the market?
Xywav, with its lower sodium content, targets patients with sodium restrictions, increasing treatment options and potentially reducing Xyrem’s market dominance.
4. What is the primary driver of revenue in this market?
High-prescription volume among a small patient population results in sustained high per-unit pricing, maintaining overall revenue.
5. Are there new therapies on the horizon?
Yes, alternative treatments and novel sleep disorder medications are in development but have yet to significantly impact the sodium oxybate market.
References
[1] Gabbott, D. A., et al. (2018). Narcolepsy: Prevalence, impact, and treatment options. Sleep Medicine Reviews, 36, 66-77.
[2] IQVIA (2022). U.S. Prescription Drug Sales Data. IQVIA Institute Reports.
[3] FDA (2020). Approval of Xywav, low-sodium formulation of sodium oxybate. Federal Register.
[4] Jazz Pharmaceuticals. (2022). Xyrem prescribing information. Product label.
